Senator Joe Manchin of West Virginia killed the Build Back Better Act. Then he wrote its replacement.
The Inflation Reduction Act, signed into law by President Joe Biden on August 16, 2022, is a budget reconciliation bill. Its sponsors are Senators Chuck Schumer (D-NY) and Joe Manchin (D-WV). That second name matters. Manchin had been the primary obstacle to the earlier, far larger Build Back Better proposal. After opposing that bill, he negotiated the text that became the Inflation Reduction Act. The legislative language was introduced as an amendment to Build Back Better, with the old text simply substituted out.
The result is a law that aims to raise $738 billion. The money comes from two sources: tax reform and prescription drug reform. The law then authorizes $891 billion in total spending. Of that, $783 billion goes to various investments. The headline numbers show a gap — $738 billion raised against $891 billion spent — but the bill is designed to reduce the federal budget deficit over time.
The spending is not vague. The law targets domestic energy production and renewable energy. Prescription drug prices are supposed to fall. These are concrete, measurable goals. The bill passed the 117th United States Congress as a budget reconciliation measure, which meant it needed only a simple majority in the Senate. No Republican votes were required. None were given.
Every Democrat in the Senate and the House voted yes. Every Republican who voted said no. The partisan split was total. That is not unusual for major legislation in the current era, but the unanimity within each party is worth noting. Not a single Democrat defected. Not a single Republican crossed over.
The law has been called landmark. That word gets thrown around. But consider the mechanics. A budget reconciliation bill cannot contain extraneous policy. It must directly affect federal spending or revenue. The Inflation Reduction Act, as a reconciliation bill, is constrained in what it can do. Yet within those constraints, it attempts to address the federal budget deficit, prescription drug prices, and energy production simultaneously. That is a broad mandate for a procedural tool designed for narrow purposes.
The bill’s path to passage was not straightforward. The Build Back Better Act, introduced earlier, was comprehensively reworked. Manchin’s opposition forced the rewrite. The final product is what emerged from those negotiations. It is shorter, more targeted, and less expensive than the original proposal. Supporters call it pragmatic. Critics call it insufficient. The report does not include quotes from either side, so those characterizations are not attributed to anyone specific.
What the report does make clear is the scale. $738 billion in new revenue. $891 billion in authorized spending. $783 billion in investments. These are not small numbers. Whether the law achieves its stated goals — lower drug prices, reduced deficit, expanded renewable energy — will depend on implementation. The law is now on the books. The work of turning those authorized dollars into actual programs and price reductions has begun.
The partisan divide suggests that the law’s impact will be debated for years. Democrats see a major achievement. Republicans see overreach. The report takes no side in that debate, but it does describe the bill as landmark. That word, from the source material, indicates the law’s significance in addressing economic and energy challenges. The report does not say whether it will succeed. It says the law is a milestone. That is a factual statement about the legislative process, not a prediction about outcomes.
